LP(A) TESTING IN A REAL-WORLD POPULATION OF US ADULTS

Study PI(s): Neha Pagidipati and Emily O’Brien, Duke Clinical Research

Project Summary: Lipoprotein (a) [Lp(a)] is a strong marker for cardiovascular (CV) risk. Perhaps because there has not been a clear therapy for elevated Lp(a), this marker is rarely checked in practice. As novel therapies become available, it will be important to increase physician awareness and testing of Lp(a). First, we must understand which patients are having their Lp(a) checked in real-world settings, and what happens to these patients.

Our goals are to:

• Describe the demographic, clinical, and laboratory characteristics of individuals with Lp(a) testing compared with those who had only LDL checked within a similar time frame
• Describe the characteristics of providers who ordered Lp(a)
• Summarize temporal patterns of Lp(a) testing in a real-world population
• Evaluate the relationship between Lp(a) level and:
  • subsequent use of lipid-lowering therapy
  • clinical outcomes

Study Design: Query based on data in the PCORnet® common data model (CDM) 4.1

PaTH Partners:

• Penn State University / Milton S Hershey Medical Center
• Ohio State University / Wexner Medical Center

Coordinating Center: Duke Clinical Research Institute